Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

“…Reactogenicity was typically mild or moderate in severity and short-lived with the majority of symptoms resolving within 3 d. An increase in local reactions is to be expected with injections close to the skin surface, as opposed to deep muscle intramuscular injections, and as reported in previous studies. [24][25][26][27][28][29] Despite the higher incidence of injection site reactions, the high satisfaction with intradermal injection system emerged from several studies in young adults and in older people and the good acceptability profile of intradermal vaccine reflects the high willingness to get re-vaccinated in the following season. 16,17,25,30 The present study demonstrated that the immunogenicity of Intanza ® 15 μg intradermal vaccine was superior than that of Inflexal ® V virosomal influenza vaccine, when the immune response was evaluated against circulating strains.…”

“…reliable and safe intradermal vaccination. 20,24 The virosomal adjuvanted vaccine (Inflexal ® V; Crucell, Switzerland) is an inactivated, subunit influenza vaccine containing the standard dosage of 15 μg HA/strain in each 0.5 ml dose and was injected intramuscularly into the deltoid muscle using a 25mm-long needle.…”

Safety, immunogenicity, and tolerability of three influenza vaccines in older adults

“…9 This is accomplished using a 30 gauge micro-needle attached to a pre-filled syringe, designed to allow highly reproducible vaccine delivery. 12 Comparisons of HAI titers following vaccination of seniors with IDV or TIV have generally shown superior responses to IDV, 9,10 with one study demonstrating non-inferiority of IDV to ADV. 13 Intradermal vaccination is reportedly less painful than intramuscular vaccination, 14 an appealing feature for the needle-averse.…”

Improving seasonal and pandemic influenza vaccines

“…The development of an easy‐to‐use, disposable microdelivery system for intradermal vaccination (Soluvia TM ; Becton Dickinson, Franklin Lakes, NJ, USA) led to the reconsideration of the intradermal route for influenza vaccination. This system has been described in detail elsewhere 27 . Briefly, it consists of a pre‐filled, ready‐to‐use syringe with an integral, narrow (30 gauge), short‐bevel micro‐needle that protrudes only 1·5 mm from the proximal end of a glass syringe.…”

“…Briefly, it consists of a pre‐filled, ready‐to‐use syringe with an integral, narrow (30 gauge), short‐bevel micro‐needle that protrudes only 1·5 mm from the proximal end of a glass syringe. It was designed and engineered based on skin anatomical requirements to ensure a consistent and reliable injection of 0·1 ml of fluid into the papillary and reticular dermis 27 , 28 …”